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Background: Amyloid β (Aβ) peptide is hypothesized to stimulate microglia to acquire their characteristic
proinflammatory phenotype in Alzheimer’s disease (AD) brains. The specific mechanisms by which Aβ leads to
microglial activation remain an area of interest for identifying attractive molecular targets for intervention. Based upon
the fact that microglia express the proinflammatory transcription factor, nuclear factor of activated T cells (NFAT), we
hypothesized that NFAT activity is required for the Aβ-stimulated microgliosis that occurs during disease.
Methods: Primary murine microglia cultures were stimulated with Aβ in the absence or presence of NFAT inhibitors,
FK506 and tat-VIVIT peptide, to quantify secretion of cytokines, neurotoxins, or Aβ phagocytosis. A transgenic mouse
model of AD, APP/PS1, was treated subcutaneously via mini-osmotic pumps with FK506 or tat-VIVIT to quantify effects
on cytokines, microgliosis, plaque load, and memory.
Results: Expression of various NFAT isoforms was verified in primary murine microglia through Western blot analysis.
Microglial cultures were stimulated with Aβ fibrils in the absence or presence of the NFAT inhibitors, FK506 and
tat-VIVIT, to demonstrate that NFAT activity regulated Aβ phagocytosis, neurotoxin secretion, and cytokine secretion.
Delivery of FK506 and tat-VIVIT to transgenic APP/PS1 mice attenuated spleen but not brain cytokine levels. However,
FK506 and tat-VIVIT significantly attenuated both microgliosis and Aβ plaque load in treated mice compared to controls.
Surprisingly, this did not correlate with changes in memory performance via T-maze testing.
Conclusions: Our findings suggest that development of specific NFAT inhibitors may offer promise as an effective
strategy for attenuating the microgliosis and Aβ plaque deposition that occur in AD.
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Alzheimer’s disease is characterized by the presence of re-
active microglia associated with amyloid β (Aβ) peptide-
containing plaques [1-4]. Since Aβ oligomers and fibrils
can serve as ligands for microglial activation, they are
often hypothesized to contribute to the proinflammatory
phenotype of microglia during disease [5-21]. In addition,
the Aβ peptides have a characterized ability to stimulate
dysregulated intracellular calcium homeostasis, in neurons
and glia, which can lead to activation of the calcium-
dependent phosphatase, calcineurin [13,22-34]. Calcine-
urin activity changes have been implicated in Alzheimer’s
disease (AD) through a variety of mechanisms including* Correspondence: colin.combs@med.und.edu
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article, unless otherwise stated.high expression and activity in the hippocampus,
calcineurin-mediated synaptic loss, neuronal death,
impaired cognition, Aβ production, and astrocyte acti-
vation [22,23,35-42].
One of the most abundant and well-studied substrates
of calcineurin is the transcription factor, nuclear factor
of activated T cells, NFAT. Although its biology has been
more classically described in the immune system [43],
numerous isoforms of NFAT are expressed in the brain
[44-48]. In order for it to become activated, NFAT is de-
phosphorylated by calcineurin for translocation to the
nucleus leading to altered immune cell behavior and
cytokine expression working in conjunction with numer-
ous other transcription factors including AP-1 and NFκB
[43,49-59]. In AD brains, various isoforms of NFAT de-
monstrate differential activation profiles with nuclear
fractions of NFAT1 (also known as NFATc2) elevated ined Central. This is an Open Access article distributed under the terms of the
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clear fractions of NFAT3 (NFATc4) are increased in AD
patient brains [38]. In addition, increased levels of the cyto-
kines, tumor necrosis factor-α (TNFα), interleukin-1 beta
(IL-1β), and granulocyte-macrophage colony-stimulating
factor (GM-CSF), positively correlate with the nuclear frac-
tion of NFAT1 in both MCI and AD tissue, thus implicat-
ing NFAT1 in neuroinflammation during early stages of
AD-related cognitive decline [38]. NFAT3 has also been
shown to be involved in neurodegenerative processes such
as neuronal cell death [46,60]. Collectively, these reports
suggest that a sequence of events involving Aβ-stimulated
or calcium dysregulation-mediated calcineurin/NFAT
activation and subsequent neuronal or glial changes
represents an attractive response pathway for thera-
peutic targeting in AD.
Because extensive work has been done to define astroglial
[38,42,47,48,61-66] and neuronal [22,23,41,44-46,67] NFAT
functions with regard to regulating proinflammatory, neu-
rodegenerative, apoptotic, sprouting, or survival responses
in the brain, we have chosen instead to examine NFAT
biology in the brain resident immune cells, microglia. It is
clear that microglia express NFAT isoforms [65,68-72] with
particularly high levels of NFATc2 [70,71]. In addition,
microglial stimulation increases NFAT activity and proin-
flammatory changes which can be attenuated using NFAT
inhibitors such as VIVIT peptide [38,42,48,63,70,73-77].
Based upon our prior work demonstrating a role for NFAT
in regulating microglial response to Aβ stimulation [71], we
continue, in this study, to define a contribution of mi-
croglial NFAT to inflammatory changes in AD using both
in vitro microglial cultures as well as the APP/PS1 trans-
genic mouse model of disease. We used two different
NFAT activation inhibitors, the clinically available small
molecule FK506 [78,79] and the cell penetrant tat-VIVIT




Anti-NFATc1 (NFAT2), anti-NFATc4 (NFAT3), anti-
NFATc3 (NFAT4), anti-phosphoNFATc2 (NFAT1), anti-
ERK2, and α-tubulin antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The anti-
MAP2 antibody was from Cell Signaling Technology Inc
(Danvers, MA, USA). HRP-conjugated secondary anti-
bodies were also obtained from Santa Cruz Biotechnology
(Dallas, TX, USA). The anti-NFATc2 (NFAT1) antibody
and FK506 were obtained from Abcam (Cambridge,
MA, USA). Anti-CD68 antibody was from AbD Serotec
(Raleigh, NC, USA). Anti-APP antibody was from Zymed
Laboratories (San Francisco, CA, USA). Elite Vectastain
ABC Avidin and Biotin, Vector VIP, biotinylated anti-rat
and anti-mouse antibodies were obtained from VectorLaboratories Inc (Burlingame, CA, USA). Synaptophysin
antibody was purchased from Chemicon International, Inc
(Temecula, CA, USA). Phospho-NFκB (p65) antibody,
NFκB (p65) antibody, PSD95 antibody, and beta site APP
cleaving enzyme (BACE) antibody were from Cell Signal-
ing Technology Inc (Danvers, MA, USA). Anti-Aβ (4G8)
antibody was from Covance (Emeryville, CA, USA). The
c-Fos antibody was purchased from Novus Biologicals,
LLC (Littleton, CO, USA). Lipopolysaccharide (LPS) and
MTT were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Human Aβ1-42 was purchased from Bachem
(Torrance, CA, USA) and fibrillized before use according
to our prior protocol [80]. A VIVIT peptide sequence,
MAGPHPVIVITGPHEE, that interacts with NFAT at its
calcineurin binding site and inhibits its activation was used
along with its negative control, VEET, peptide [73]. A cell-
permeable variation of VIVIT peptide, tat-VIVIT, fused
with an HIV-1 TAT protein cationic transduction domain
[76,77], was generated to examine the potential of this
novel peptide construct for NFAT inhibition as in our
prior work [70]. The inhibitory peptide tat-VIVIT
(H-YGRKKRRQRRR-AA-MAGPHPVIVITGPHEE-NH2)
and negative control peptide, tat-VEET (H-YGRKKRRQ
RRR-AA-MAGPPHIVEETGPHVI-NH2), were synthesized
by Dr. Satya Yadav at the Molecular Biotechnology Core
Laboratory at the Cleveland Clinic Foundation (Cleveland,
OH). Cytokine enzyme-linked immunosorbent assay
(ELISA) kits for TNFα, interleukin-6 (IL-6), IL-1β were
purchased from R&D Systems (Minneapolis, MN, USA).
Fluorescein isothiocyanate (FITC) bioparticles were pur-
chased from Invitrogen (Carlsbad, CA, USA).
Animals
All animal use was approved by the University of North
Dakota Institutional Animal Care and Use Committee
(UND IACUC). The Jackson Laboratory (Bar Harbor, ME)
transgenic mouse line, strain 005864 B6.Cg-Tg (APPswe,
PSEN1dE9)85Dbo/J, and their wild-type littermate con-
trols were used for this study. Mice were provided food
and water ad libitum and housed in a 12-h light:dark
cycle. The investigation conforms to the National Re-
search Council of the National Academics Guide for the
Care and Use of Laboratory Animals (eighth edition).
These APP/PS1 transgenic mice express the human APP,
Aβ precursor protein (A4) with the Swedish mutations
K595N/M596L, and the human PSEN1, presenilin 1 with
the DeltaE9 mutation under control of the mouse prion
promoter.
Cell culture
Primary microglia were derived, as described previously
[8], from the brains of postnatal day 1 to 3 wild-type
C57BL/6 wild type mice. Briefly, meninges-free cortices
were removed, trypsinized, and triturated in microglia
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trogen, Carlsbad, CA, USA) and 20% heat-inactivated
FBS) and placed in T-75 flasks. Media in the flasks was re-
placed completely after 24 h and partially after 7 days with
fresh media. Cells were harvested, counted, and used at
day 14 in vitro.
Neurons were cultured from cortices of wild-type
embryonic day 16 (E16) mice (C57BL/6). Meninges-free
cortices were isolated, trypsinized, and plated onto poly-L-
lysine-coated tissue culture wells containing Neurobasal
media with L-glutamine and B27 supplements (Invitrogen,
Rockville, MD, USA). Neurons were allowed to grow in
the media for 7 days in vitro in order to provide >95%
purity.
Jurkat cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and
maintained in RPMI-1640 medium (Gibco RBL, Rockville,
MD, USA) containing 10% heat-inactivated fetal bovine
serum (US Biotechnologies Inc., Parkerford, PA, USA),
5 mM HEPES, and 1.5 μg/mL antibiotics (penicillin/
streptomycin/neomycin).
Cell stimulations
To determine the levels of proinflammatory cytokines,
cells were pretreated with FK506 or tat-VIVIT for
30 min followed by 10 μM Aβ 1-42 stimulation for 24 h.
Media was collected for ELISA.
In order to understand the effect of NFAT inhibition
on neuronal cell viability, 7-day in vitro primary neurons
were grown in microglial conditioned media for 72 h as
previously described [25]. Briefly, 96-well cell culture
plates were coated with Aβ 1-42 fibrils (48 pmole/mm2)
in the presence or absence of 0.1 μM FK506 and 1 μM
FK506 in serum-free Neurobasal media with B27 supple-
ments. Microglia cells were plated on the surface-bound
Aβ fibrils for 48 h. Following the stimulation, media
from wells with only Aβ (negative control), wells with
only microglia, and conditioned media from wells with
microglia stimulated with Aβ were transferred to neu-
rons for 72 h. Neurons were also left untreated or
treated with 0.1 μM FK506 or 1 μM FK506 added to the
neurons along with the conditioned media. Following all
the treatments, neurons were fixed with 4% paraformal-
dehyde and immunostained with anti-MAP2 antibody.
As in our prior work [25], surviving cells immunostained
positive for MAP2 were counted, averaged, and plotted
(±SD). Stimulations were performed in duplicate and re-
peated three times. A counting grid was placed over the
wells to count the number of neurons from eight identi-
cal fields for each condition.
ELISA
The levels of proinflammatory cytokines TNFα, IL-6,
and IL-1β were measured using ELISA. Media from cellstimulation experiments was transferred onto ELISA
plates and levels measured using the manufacturer’s
protocol. For brain and spleen ELISA, flash-frozen hippo-
campi or spleen tissue was lysed in radioimmunoprecipita-
tion assay (RIPA) buffer and lysates were centrifuged at
14,000 rpm, 4°C, for 10 min to remove any insoluble ma-
terial. Supernatants were then transferred onto the ELISA
plates and cytokine levels were measured and averaged
(±SD) as per the manufacturer protocol.
MTT reduction assay
Cell viability was measured using the MTT reduction assay.
After 24-h stimulation with Aβ in the presence or absence
of FK506 or tat-VIVIT, cells were treated with 0.1 mg/mL
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) for 4 h at 37°C. The media was aspirated and
precipitated formazan dissolved with isopropanol. Optical
density was measured at 560 nm, averaged (±SD), and
plotted.
Phagocytosis assay
In order to determine the phagocytic ability of Aβ-
stimulated microglia in the presence or absence of
NFAT inhibitors, microglia were plated onto 96-well cul-
ture plates and were either untreated or treated with
1 μM FK506 for 24 h. Cells were then treated with either
500 nM FITC-conjugated Aβ1-42 fibrils or 0.25 mg/mL
FITC-conjugated bioparticles for an additional 6 h. After
incubation, the media was removed and fluorescence
from extracellular peptide or membrane-bound bioparti-
cles was quenched via a rinse with 0.25% trypan blue.
Fluorescence intensity from phagocytosed peptide and
bioparticles was measured using a fluorescent plate
reader (480-nm excitation and 520-nm emission) and
averaged (±SD).
Animal treatments
NFAT inhibitors FK506, tat-VIVIT, and tat-VEET were
infused subcutaneously into male APP/PS1 mice at
12 months of age. The compounds were delivered via
mini-osmotic pumps (model 1004, 0.11 μL/h delivery
rate for 28 days, Alzet, Cupertino, CA, USA). Pumps de-
livered either vehicle (DMSO/HEPES) (n = 8), FK506
(1 mg/kg/day) (n = 7), VIVIT (0.5 mg/kg/day) (n = 8), or
negative control scrambled peptide, VEET (0.5 mg/kg/day)
(n = 8), for 28 days. At the end of the infusion period, mice
were behaviorally tested (day 28 of 28-day infusion) then
euthanized and perfused with PBS-CaCl2, and brains and
spleens were rapidly collected. Control untreated APP/
PS1 mice were collected at a comparable age of comple-
tion, 13 months (n = 6). The right hemispheres of the
brains were fixed in 4% paraformaldehyde, and the left
hemispheres were flash frozen in liquid nitrogen for bio-
chemical analysis.
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Temporal cortices were dissected out of the left brain
hemispheres from the control, the vehicle-treated, or the
inhibitor-infused mice and lysed, sonicated in RIPA buffer,
and quantitated using the Bradford method [81]. The
lysates were resolved on 10% SDS-PAGE and transferred
to polyvinylidene difluoride membranes for Western blot-
ting using anti-APP, anti-BACE, anti-synaptophysin, anti-
PSD95, anti-pNFκB (p65), and anti-pNFATc2 antibodies
with anti-α-tubulin, NFκB (p65) (for pNFκB), and NFATc2
(for pNFATc2) antibodies used for loading controls.
Western blots were quantified using Adobe Photoshop
software. Optical densities (O.D.) of bands were nor-
malized against their respective loading controls and
averaged (±SD).
Immunohistochemistry
Right hemispheres from brains collected from un-
treated or NFAT inhibitor-infused mice were fixed in
4% paraformaldehyde and cryoprotected in 30% su-
crose (in 0.1 M phosphate buffer) by replacing the su-
crose solution every 3 to 4 days at least three times.
The fixed tissue was then embedded in a 15% gelatin
matrix, and the gelatin block again fixed in 4% parafor-
maldehyde for 3 to 4 days followed by cryoprotection
in 30% sucrose solution. The block was then flash fro-
zen using dry ice/isopentane and serially cut (40 μm)
on a freezing microtome. Serial sections were used for
immunostaining using anti-Aβ (4G8) and anti-CD68
(macrophage/microglia marker) antibodies using Vector
VIP as the chromogen. In order to quantitate immu-
nostaining, ×1.25 pictures of three consecutive sections
(960 μm apart) throughout the temporal cortex region
were taken. Optical densities from hippocampi from
each brain section were measured using Adobe Photo-
shop software. The optical density values per condition
(five conditions), per brain (six to eight brains per con-
dition) and per section (three sections per brain) were
obtained, averaged (±SD), and plotted.
T-maze
T-maze analysis was performed as described by Wenk
[82]. Briefly, on the 28th day after initiation of infu-
sion, the mice were placed into the starting arm of
the T-maze and the door was raised to allow the
mice to walk down the stem and enter an arm. Once
a mouse entered an arm with all four paws, it was
returned to the starting arm. The door was closed for
30 s, then raised, and the mouse was allowed to
move freely until it entered an arm again. The
process was repeated for nine trials and the choice of
arms that mice entered was noted. The number of al-
ternations per mouse in each condition was averaged
(±SD) and plotted.Statistical analyses
Data are presented as mean values ± SD. Statistical sig-
nificances were calculated using one-way ANOVA with
Tukey-Kramer’s post hoc comparison and considered
significant when p values were <0.05.
Results
Microglia expressed multiple NFAT isoforms
In order to compare microglia expression of NFAT to
peripheral immune cells, we compared primary murine
microglia to the human T cell line, Jurkat. Based upon
the fact that NFAT isoforms in both humans and mice
each demonstrate a multitude of alternative splice pat-
terns, we expected a diverse range of protein expres-
sion patterns per isoform [83]. As predicted, Western
blot analysis demonstrated that Jurkat cells expressed
multiple molecular weight NFAT isoforms (Figure 1).
Although primary murine microglia also displayed de-
tectable amounts of numerous molecular weight spe-
cies, only NFATc1, NFATc2, and NFATc4, and not
NFATc3, were detectable (Figure 1).
Microglial NFAT activity was required for increased
cytokine secretion following stimulation
In order to determine whether increased NFAT activity
was required for altered protein expression in microglia,
we next collected media from microglia stimulated 24 h
with Aβ or LPS in the absence or presence of tat-VIVIT
or FK506 treatments to inhibit NFAT [70,73]. ELISAs
for TNFα and interleukin-6 (IL-6) were performed from
the media to quantitate any changes in cytokine secre-
tion. Although Aβ treatment alone had an expected
slight decrease in cell viability, neither tat-VIVIT nor
FK506 further decreased survival (Figure 2). On the
other hand, both tat-VIVIT and FK506 significantly at-
tenuated both Aβ- and LPS-stimulated secretion of ei-
ther cytokine (Figure 2).
NFAT activation increased microglial uptake of fibrillar Aβ
Decreasing proinflammatory secretion from microglia is
arguably an advantageous condition in the AD brain, but
decreasing phagocytic ability in parallel may lead to an
undesirable increase in fibrillar Aβ plaque deposition.
To determine whether NFAT inhibition attenuated mi-
croglial ability to clear fibrillar Aβ via phagocytic uptake,
microglia were stimulated with FK506 and uptake of
FITC-conjugated Aβ1-42 fibrils was quantified. In con-
trast to the inhibitory consequence of FK506 treatment
with regard to cytokine secretion, drug treatment actu-
ally increased phagocytic uptake of Aβ fibrils (Figure 3).
Moreover, this was not limited to Aβ. Phagocytosis of
FITC-labeled bioparticles was also increased following
FK506 treatment suggesting that the benefits were not
specific to a particular particle type (Figure 3).
Figure 1 Microglia expressed multiple NFAT isoforms. Microglia
were grown as mixed glial cultures from postnatal day 0 C57BL6/J
mice and purified at day 14 in vitro. Lysates of microglia (M) were
compared to lysates from the Jurkat human T cell line (J) via
Western blot using anti-NFATc1, c2, c3, c4, α-tubulin, and ERK-2
(loading control) antibodies. Multiple bands per NFAT isoform likely
reflect the multiple alternative transcripts reported for each isoform.
Blots are representative of three independent experiments.
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microglial-mediated neuron death in vitro
Another demonstrative therapeutic advantage of NFAT
inhibition in AD would be evidence of neuroprotection.
To generate evidence of whether or not microglial NFAT
inhibition could improve neuron survival in AD, we next
stimulated microglia with and without Aβ fibrils in the
absence or presence of FK506 and transferred this con-
ditioned media to primary cortical neuron cultures. Our
prior work has demonstrated that this Aβ-stimulated
conditioned media is potently toxic to neuron cultures
compared to media from unstimulated microglia [84].
Treatment of the microglia with FK506 attenuated the
toxicity of Aβ-stimulated conditioned media (Figure 4).
Importantly, this neuroprotection was via microglial in-
hibition since adding FK506 directly to neurons in the
presence of the Aβ-stimulated conditioned media had
no ability to offer protection (Figure 4).
Tat-VIVIT and FK506 attenuated microgliosis in a
transgenic mouse model of Alzheimer’s disease
In order to test the efficacy of NFAT inhibition for par-
ticularly microglial activation in vivo, we next relied on a
transgenic mouse model of AD with robust microgliosis
[80]. Using an APP/PS1 transgenic mouse model of AD,
we tested the efficacy of NFAT inhibition as a thera-
peutic for AD. APP/PS1 mice were treated, for 28 days
via mini-osmotic pumps, with either FK506 or the
brain-permeable NFAT inhibitory peptide, tat-VIVIT.
Immunostaining for CD68, the microglial marker, dem-
onstrated that both FK506 and tat-VIVIT but not the
negative control-scrambled peptide, tat-VEET [74], sig-
nificantly attenuated CD68 immunoreactivity in the
hippocampus of the mice as predicted (Figure 5).
Tat-VIVIT and FK506 reduced Aβ plaque load in a
transgenic mouse model of Alzheimer’s disease
In order to determine whether microglial inhibition re-
sulted in any change in plaque load in these mice, Aβ
immunoreactive plaques were stained from serial hippo-
campal sections from the mice using the anti-Aβ anti-
body, 4G8. Plaque density was quantified to reveal that
both FK506 and tat-VIVIT attenuated Aβ peptide-
containing plaque load (Figure 6). This suggested that
decreasing reactive microglial phenotype via NFAT in-
hibition had an additional beneficial effect of also de-
creasing plaque load.
Tat-VIVIT and FK506 reduced cytokine secretion
peripherally in a transgenic mouse model of Alzheimer’s
disease
The brains and spleens of these mice were next used to
measure changes in NFAT activity and cytokine levels to
determine whether the decreases in microglial and Aβ
Figure 2 FK506 and tat-VIVIT attenuated Aβ-stimulated TNFα secretion by microglia. Microglia were stimulated with 10 μM Aβ1-42 fibrils
for 24 h in the absence or presence of 1 μM FK506 or 10 μM tat-VIVIT. (A) Media aliquots were taken and ELISAs were performed to quantitate
levels of secreted TNFα. (B) Media was also taken to perform LDH release assays to quantitate cell death. Conditions were performed with eight
repeats and averaged (±SD). Graphs are representative of three independent experiments (*p < 0.001 from control).
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crease in NFAT activity and anti-inflammatory effects after
FK506 or tat-VIVIT treatment. Although FK506 signifi-
cantly decreased IL-6, TNFα, and IL-1β levels in the
spleens of mice, tat-VIVIT treatment significantly attenu-
ated only IL-6 and TNFα levels (Figure 7). Unexpectedly,
tat-VIVIT or FK506 treatment had no effect on levels of
brain cytokines (Figure 8) in spite of the changes observed
in the spleen (Figure 7) and the significant decrease in
microglial immunoreactivity observed (Figure 5). This
suggests that a higher concentration of either drug may berequired for quantifiable brain anti-inflammatory, NFAT
inhibitory effects.
In order to continue characterizing the effects of tat-
VIVIT or FK506 treatment on the brain, we performed
Western blot analyses to quantify any additional differ-
ences due to NFAT inhibitor treatment. Although NFATc1
activity was not different between treatment groups, it was
possible that other NFAT isoforms were affected by treat-
ments. Active levels of NFATc2 were quantified by measur-
ing any change in phosphorylation state. However, similar
to NFATc1 no increase in active, non-phosphorylated
Figure 3 FK506 stimulated increased microglial uptake of Aβ fibrils. Microglia were plated in the absence or presence of 1 μM FK506 for
24 h. Either 500 nM FITC-conjugated Aβ1-42 fibrils or 0.25 mg/mL FITC-conjugated bioparticles were added to the cells for an additional 6 h.
After incubation, the media was removed and the signal from unphagocytosed peptide was quenched with trypan blue. Fluorescence intensity from
phagocytosed peptide and bioparticle was quantitated using a fluorescent plate reader (480-nm excitation and 520-nm emission) and averaged (±SD).
Conditions were performed with eight repeats per condition and graphs are representative of three independent experiments (±SD) (*p < 0.001 from
control, #p < 0.05 from Aβ, %p < 0.001 from bioparticle).
Figure 4 FK506 prevented microglial generation of neurotoxic conditioned media following Aβ stimulation. Microglia were stimulated
48 h in the absence or presence of surface-bound Aβ1-42 fibrils (48 pmole/mm2) and 0.1 and 1 μM FK506. Conditioned media from bound Aβ
wells alone (negative control), microglia only wells (microglia CM), and Aβ-stimulated microglia wells (Aβ-stimulated microglia CM) +/− FK506
were transferred to 7 day in vitro primary mouse cortical neuron cultures for 72 h. In addition, FK506 (0.1 and 1 μM) was added directly to
neurons (negative control) and to neurons along with Aβ-stimulated microglia. Neurons were fixed and stained with an anti-MAP2 antibody and
surviving cells counted and averaged (±SD). Stimulations were performed in duplicate and repeated three times. Results are the average of three
independent experiments (*p < 0.001 from control).
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Figure 5 FK506 and tat-VIVIT decreased CD68 immunoreactivity in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were treated via
subcutaneous delivery for 28 days with no treatment (control), vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or 0.5 mg/kg/day negative
control scrambled peptide, VEET (n = 6 to 8/condition). Brains were collected, sectioned, and stained using anti-CD68 antibody and staining intensities
were quantified from serial sections from the hippocampus. The optical density values per condition (five conditions), per brain (six to eight brains per
condition), and per section (three sections per brain) were obtained, averaged (±SD), and plotted (***p < 0.001).
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Figure S1). To determine whether the decrease in Aβ
plaque levels could be due to altered levels of APP or its
processing, APP and BACE were quantified. Again, no dif-
ferences were observed in any treatment (Additional file 1:Figure 6 FK506 and VIVIT decreased Aβ plaque load in APP/PS1 mice. T
delivery for 28 days with no treatment (control), vehicle DMSO, 1 mg/kg/day
peptide, VEET (n = 6 to 8/condition). Brains were collected, sectioned, and stai
from serial sections from the hippocampus. The optical density values per con
per section (three sections per brain) were obtained, averaged (±SD), and ploFigure S1). To examine whether changes in other tran-
scription factors might correlate with the effects we
observed, protein levels of c-Fos and phosphorylated, ac-
tive p65 NFκB were also examined. However, similar to
NFATc2, no differences were observed between groupswelve-month-old male APP/PS1 mice were treated via subcutaneously
FK506, 0.5 mg/kg/day VIVIT, or 0.5 mg/kg/day negative control scrambled
ned using anti-Aβ (4G8) antibody and staining intensities were quantified
dition (five conditions), per brain (six to eight brains per condition), and
tted (***p < 0.001).
Figure 7 FK506 and tat-VIVIT decreased spleen cytokine levels
in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were treated
via subcutaneous delivery for 28 days with no treatment (control),
vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or
0.5 mg/kg/day negative control scrambled peptide, VEET (n = 6
to 8/condition). Spleens were collected, lysed, and used for TNFα,
IL-1β, and IL-6 ELISAs. (*p < 0.05, **p < 0.01 from control; $p < 0.01,
$$p < 0.01 from vehicle; +p < 0.05 from VIVIT; &&p < 0.01 from FK506)
Figure 8 FK506 and tat-VIVIT did not affect brain cytokine levels
in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were treated
via subcutaneous delivery for 28 days with no treatment (control),
vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or 0.5 mg/kg/
day negative control scrambled peptide, VEET (n = 6 to 8/condition).
Hippocampi were collected, lysed, and used for TNFα and IL-6 ELISAs.
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were assessed by quantifying protein levels of the pre-
synaptic marker, synaptophysin, and the postsynaptic
marker, PSD95. No differences were observed between
groups (Additional file 1: Figure S1).FK506 and tat-VIVIT did not improve spatial memory in
APP/PS1 mice
In order to determine whether an NFAT inhibition-
mediated decrease in microgliosis had an effect on behav-
ior of APP/PS1 mice, we performed T-maze analyses to
quantify working memory. Mice infused with tat-VIVIT or
FK506 did not show any changes in the performance on
T-maze as measured by the number of alternations be-
tween the T-maze arms (Figure 9).
Discussion
Collectively, these results demonstrated that microglia ex-
press multiple NFAT isoforms which have a role in regu-
lating the Aβ-stimulated increase in cytokine secretion.
Importantly, inhibition of NFAT with tat-VIVIT or FK506
was sufficient to attenuate cytokine secretion and neuron
death yet increase Aβ phagocytic uptake in vitro. Similarly,
peripheral delivery of tat-VIVIT or FK506 to APP/PS1
mice decreased levels of reactive microglia and Aβ immu-
noreactive plaque load in the brain. However, this did not
correlate with changes in either brain NFAT activity or
Figure 9 FK506 and tat-VIVIT did not improve spatial memory
in APP/PS1 mice. Twelve-month-old male APP/PS1 mice were
treated via subcutaneous delivery for 28 days with no treatment
(control), vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT, or
0.5 mg/kg/day negative control scrambled peptide, VEET (n = 6 to
8/condition). Mice were used for T-maze testing on day 28. Numbers
of spontaneous alternations were averaged and graphed (±SD).
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of specific NFAT inhibitors, perhaps independent of the
ability to traverse the blood brain barrier, may offer prom-
ise for attenuating the microgliosis and Aβ deposition that
occur in AD.
Our findings are consistent with numerous other re-
ports suggesting that NFAT activity is a reasonable anti-
inflammatory target in AD. It has been shown from AD
brain hippocampi that levels of several cytokines, includ-
ing IL-1β, TNFα, and GM-CSF, are elevated in correl-
ation with nuclear accumulation of NFAT1 (NFATc2)
[85]. In addition, Aβ-mediated neurotoxicity is attenu-
ated by NFAT inhibition in APP/PS1 following injection
of VIVIT into the cortex [41]. We have found that
microglial NFAT may also be important in regulating
the complex milieu of the inflammatory environment of
the diseased brain. Future work may define whether par-
ticular isoforms of NFAT in one cell type versus another
are more effective at preventing inflammatory changes.
Although we have shown that FK506 and tat-VIVIT
were effective in counteracting Aβ-mediated effects on
microglial in vitro and attenuating microgliosis in the
APP/PS1 line, we appreciate that neither of these agents
is NFAT isoform selective. Indeed, FK506 has the added
confound of inhibiting calcineurin activity [86]. There-
fore, we cannot exclude the possibility that some of the
changes we observed from FK506 treatment were due to
calcineurin inhibition. Indeed, several others have re-
ported the preclinical benefits of calcineurin inhibition
in mouse models of AD [22,42,87-91]. Our intent was to
contrast the effects of the tat-VIVIT treatment with
those of FK506 due to the fact that the VIVIT peptide
has no reported ability to inhibit calcineurin [73,92,93].
In this way, we predicted that it might be possible todetermine, to some extent, how much of the anti-
inflammatory effects were due to calcineurin versus
NFAT inhibition. In addition, it is important to point
out that some of the decrease in cytokine secretion we
observed in our in vitro experiments could be due to a
loss of viability from the Aβ treatment itself. However,
the dose-dependent inhibitory effect of the VIVIT pep-
tide treatment on TNFα secretion still exists in spite of a
similar reduction in Aβ treatment across all conditions.
Nevertheless, future work will require a lower, nontoxic
concentration of peptide below 10 μM to prevent the
confound of toxicity we observed.
It is likely that the concentrations or delivery method of
our FK506 and tat-VIVIT for the in vivo experiments was
not optimum. For example, despite the fact that both
FK506 and tat-VIVIT peptide attenuated spleen peripheral
cytokine levels, we did not observe the same changes in
the brain. Indeed, much higher concentrations have been
reported for both FK506 [88,90] and VIVIT peptide
[41,63,75] to achieve brain effects. Although FK506 has
been used at a dosage of 1 mg/kg/day, similar to our own,
to attenuate hippocampal atrophy and microgliosis in a
tauopathy mouse model [94], others have reported im-
proved cognitive function and spine density restoration
using much higher concentrations of the drug ranging
from 10 to 100 mg/kg/day of FK506 [88,90]. Similarly,
studies showing effects of VIVIT in inhibiting Aβ-
mediated neurodegeneration involve viral vector overex-
pression of VIVIT in the cortex or hippocampus likely
reaching much higher local concentrations than our para-
digm [41,63]. A study similar to our own using peptide ra-
ther than an expression system for VIVIT demonstrated a
role for NFAT in cardiac hypertrophy and involved inject-
ing VIVIT at a dose of 10 mg/kg subcutaneously [75].
Therefore, it is quite possible that the brain concentrations
of drug and peptide we achieved were simply not high
enough to inhibit NFAT activity during our delivery para-
digm. This possibility is consistent with the fact that we
were not able to quantify any decrease in active NFATc2
levels in the FK506- and tat-VIVIT-infused mouse brains.
In this case, higher drug or peptide concentrations or dir-
ect brain delivery might achieve more robust anti-gliotic
and anti-inflammatory effects in future work. Although it
is not clear what adverse effects would result from higher
concentration or more prolonged delivery of the VIVIT
peptide, it is clear that higher concentrations of FK506, in-
cluding levels used in prior rodent work, can have a range
of adverse effects in both rodents and humans, particularly
nephrotoxicity [87,91]. It is intriguing to note that in spite
of no quantifiable decrease in NFAT activity or brain cyto-
kine levels, the concentrations of both FK506 and tat-
VIVIT peptide still significantly decreased microgliosis
and plaque load in the mice. We recognize that our
method of indirectly assessing NFATc2 activity changes
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is not the most sensitive or reliable means of assessing
changes in binding ability. Future work employing electro-
mobility shift assays would undoubtedly provide a clearer
indication of changes in activity in both the periphery and
the brain. We speculate that one possibility for the de-
crease in plaque load was simply due to improved clear-
ance from the brain via increased microglial phagocytic
ability. This suggests the provocative possibility that the
modest changes in peripheral cytokine levels and presum-
ably NFAT inhibition are enough to produce dramatic and
significant effects on the brain. A further extension of this
idea would be to determine whether modulation of per-
ipheral NFAT activity and resultant cytokine or immune
cell behavior is sufficient to limit brain inflammation. It is
even feasible that peripheral NFAT inhibition is sufficient
to limit infiltration of blood-derived immune cells into the
brain, thus minimizing any exacerbation of an inflamma-
tory response provided by the influxing peripheral leuko-
cytes. In fact, NFATc2 has been shown in prior work to be
particularly important in regulating glioblastoma invasion
[85]. A strategy of peripheral NFAT targeting may eli-
minate or minimize the need for specific brain anti-
inflammatory drugs to actually require brain penetration.
Regardless of the precise mechanism by which FK506
or tat-VIVIT treatment led to reduction in microgliosis
and plaque load, it is still surprising that this did not re-
sult in improved performance via T-maze testing. It is
possible that the testing paradigm we employed was not
sufficiently sensitive enough to detect behavioral changes
that result from the modest decrease in plaque load we
observed. Additional memory testing protocols and
more prolonged or robust drug regimens may provide
changes that are quantifiable in the mouse model.
Conclusions
These data support the idea that Aβ-mediated micro-
gliosis and cytokine secretion is regulated, in part, by
NFAT activity. Further studies to determine the appro-
priate dosage and treatment paradigms for FK506 and
tat-VIVIT as well as to identify novel, brain penetrant
NFAT inhibitors may provide a therapeutic approach for
limiting the inflammatory component of AD.
Additional file
Additional file 1: Figure S1. FK506 and tat-VIVIT did not alter brain protein
levels or active NFATc2 levels in APP/PS1 mice. Twelve-month-old male
APP/PS1 mice were treated via subcutaneous delivery for 28 days with no
treatment (control), vehicle DMSO, 1 mg/kg/day FK506, 0.5 mg/kg/day VIVIT,
or 0.5 mg/kg/day negative control scrambled peptide, VEET (n= 4/condition).
Temporal cortices were collected, lysed, and separated by SDS-PAGE and
Western blotted using anti-APP, BACE, PSD95, synaptophysin, pNFATc2,
NFATc2 (loading control), anti-pNFκB (p65), anti-NFκB (p65) (loading
control), c-Fos, and βIII tubulin (loading control) antibodies. Opticaldensities were normalized against their respective loading controls,
averaged, and graphed (±SD).
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